AU4358701A - Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences - Google Patents

Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences

Info

Publication number
AU4358701A
AU4358701A AU4358701A AU4358701A AU4358701A AU 4358701 A AU4358701 A AU 4358701A AU 4358701 A AU4358701 A AU 4358701A AU 4358701 A AU4358701 A AU 4358701A AU 4358701 A AU4358701 A AU 4358701A
Authority
AU
Australia
Prior art keywords
preventing
respiratory virus
infeciton
methods
polynucleotide sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU4358701A
Other languages
English (en)
Inventor
Gary Van Nest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax Technologies Corp
Original Assignee
Dynavax Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corp filed Critical Dynavax Technologies Corp
Publication of AU4358701A publication Critical patent/AU4358701A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU4358701A 2000-03-10 2001-03-12 Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences Pending AU4358701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18858300P 2000-03-10 2000-03-10
US09/802,686 US20010046967A1 (en) 2000-03-10 2001-03-09 Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
PCT/US2001/007839 WO2001068116A2 (en) 2000-03-10 2001-03-12 Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections

Publications (1)

Publication Number Publication Date
AU4358701A true AU4358701A (en) 2001-09-24

Family

ID=26884244

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4358701A Pending AU4358701A (en) 2000-03-10 2001-03-12 Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences
AU2001243587A Ceased AU2001243587C1 (en) 2000-03-10 2001-03-12 Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001243587A Ceased AU2001243587C1 (en) 2000-03-10 2001-03-12 Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences.

Country Status (8)

Country Link
US (3) US20010046967A1 (https=)
EP (1) EP1261352B1 (https=)
JP (1) JP2003526672A (https=)
AT (1) ATE476983T1 (https=)
AU (2) AU4358701A (https=)
CA (1) CA2402268C (https=)
DE (1) DE60142775D1 (https=)
WO (1) WO2001068116A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0879284B1 (en) * 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
EP1322655B1 (en) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
ATE350015T1 (de) * 2000-09-28 2007-01-15 Novartis Vaccines & Diagnostic Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
CA2451974C (en) 2001-06-21 2014-10-14 Karen L. Fearon Chimeric immunomodulatory compounds and methods of using the same
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
JP4607452B2 (ja) * 2001-08-07 2011-01-05 ダイナバックス テクノロジーズ コーポレイション 免疫調節性組成物、製剤およびその使用方法
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
AU2003304107B2 (en) * 2002-11-01 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PT1992635E (pt) 2002-12-23 2012-03-20 Dynavax Tech Corp Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004110483A1 (en) * 2003-05-31 2004-12-23 Yiyou Chen Method and composition of a novel vaccine design for the prevention and treatment of sars
US20080027006A1 (en) * 2004-02-12 2008-01-31 The Regents Of The University Of Colorado Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity
AU2006220835B2 (en) 2005-03-04 2012-01-19 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1874325A2 (en) * 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
WO2008057529A2 (en) * 2006-11-06 2008-05-15 Coley Pharmaceutical Group, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
US8815817B2 (en) * 2008-05-15 2014-08-26 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
ES2534947T3 (es) 2009-03-25 2015-04-30 The Board Of Regents Of The University Of Texas System Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
AU2022210426A1 (en) * 2021-01-19 2023-08-24 Nortiva Bio, Inc. Gastric residence systems for administration of risperidone

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5015733A (en) * 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5093232A (en) * 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5015882A (en) * 1986-09-03 1991-05-14 Texas Instruments Incorporated Compound domino CMOS circuit
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5616461A (en) * 1992-05-14 1997-04-01 Dana-Farber Cancer Institute Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
EP0879284B1 (en) 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2289741A1 (en) 1997-05-19 1998-11-26 Merck & Co., Inc. Oligonucleotide adjuvant
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DK1009413T3 (da) * 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1077708A1 (en) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
ATE305507T1 (de) * 1998-05-14 2005-10-15 Coley Pharm Gmbh Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
WO2000016804A1 (en) 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
EP1117433A1 (en) 1998-10-09 2001-07-25 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
WO2000062802A2 (en) * 1999-04-20 2000-10-26 Smithkline Beecham Biologicals Sa Vaccine comprising rsv antigen and cpg oligonucleotide
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
CA2380947C (en) 1999-08-19 2011-11-01 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
EP1253947A4 (en) * 2000-01-31 2005-01-05 Univ California IMMUNOMODULATORY POLYNUCLEOTIDES FOR THE TREATMENT OF INFECTION BY AN INTRACELLULAR PATHOGEN
AU4175101A (en) * 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
CA2404041A1 (en) * 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
WO2001076642A1 (en) 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines

Also Published As

Publication number Publication date
CA2402268A1 (en) 2001-09-20
AU2001243587C1 (en) 2006-11-16
DE60142775D1 (de) 2010-09-23
AU2001243587B2 (en) 2005-11-24
JP2003526672A (ja) 2003-09-09
US20010046967A1 (en) 2001-11-29
EP1261352A2 (en) 2002-12-04
WO2001068116A3 (en) 2002-08-08
ATE476983T1 (de) 2010-08-15
WO2001068116A2 (en) 2001-09-20
CA2402268C (en) 2012-10-02
US8226957B2 (en) 2012-07-24
US20100035975A1 (en) 2010-02-11
US20040009942A1 (en) 2004-01-15
EP1261352B1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
AU4358701A (en) Methods of preventing and treating respiratory viral infeciton using immunomodulatory polynucleotide sequences
WO2001068077A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
WO2001068103A3 (en) Treatment of herpes infection using immunomodulatory polynucleotide sequences
WO2001068117A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
AU4203201A (en) Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
AU7144901A (en) Human papilloma virus treatment
NO20070551L (no) Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon.
EP1618889A3 (en) Influenza Vaccine
MXPA05005203A (es) Vacuna contra vhc.
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
TW200509961A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
DK0915707T3 (da) Farmaceutiske sammensætninger omfattende serumamyloid P-komponent til profylaktisk eller terapeutisk behandling af virusinfektioner og kit til detektering af sammensætningers binding til viruskomponenter
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
AU6365301A (en) Vaccine
WO2003061602A3 (en) Combination therapy for treatment of hiv infection
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
WO2007121491A8 (en) Hcv vaccinations
AU3431397A (en) Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
WO2004108756A3 (en) Sars coronavirus peptides and uses thereof
WO2002078717A3 (en) Compositions and methods for reducing rna virus pathogenicity
WO2022146154A3 (en) Peptide for use in the treatment or prevention of covid-19